Clinical Use, Population-Level Impact, and Antimicrobial Resistance Considerations of Probiotics and Microbiome-Based Therapeutics: Review
Pharmacoepidemiology · 15.01.2026 · 5 (1) · 3
DOI: 10.3390/pharma5010003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology, online erschienen am 15.01.2026. Verfasst von Monthon Lertcanawanichakul und 3 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal Initiative of Her Royal Highness Princess Maha Chakri Sirindhorn (RSPG), Thailand.
Abstract (Originalsprache)
Probiotics and microbiome-based therapeutics are increasingly used to prevent antibiotic-associated diarrhea (AAD) and support gut microbiota health across children, adults, and elderly populations. Evidence synthesized in this narrative review from randomized controlled trials and meta-analyses (>20,000 participants) suggests that early probiotic administration, particularly Lactobacillus rhamnosus GG, Bifidobacterium species, multistrain formulations, and Saccharomyces boulardii, is associated with a 30–40% relative reduction in AAD incidence across heterogeneous studies, with absolute risk reductions of approximately 5–12% depending on baseline risk, strain, dose, and timing. Probiotics are generally well tolerated, with mild gastrointestinal adverse effects reported in 3–5% of users and rare serious events mainly in immunocompromised individuals. However, heterogeneity in formulations, populations, and limited long-term real-world data underscores the need for further pharmacoepidemiological studies, microbiome surveillance, and evaluation of antimicrobial resistance implications.
Förderung
- Royal Initiative of Her Royal Highness Princess Maha Chakri Sirindhorn (RSPG), Thailand
Zitieren
APA
Lertcanawanichakul, M., Bhoopong, P., Madoromae, H., & Sahabuddeen, T. (2026). Clinical Use, Population-Level Impact, and Antimicrobial Resistance Considerations of Probiotics and Microbiome-Based Therapeutics: Review. Pharmacoepidemiology, 5(1), 3. https://doi.org/10.3390/pharma5010003
Vancouver
Lertcanawanichakul M, Bhoopong P, Madoromae H, Sahabuddeen T. Clinical Use, Population-Level Impact, and Antimicrobial Resistance Considerations of Probiotics and Microbiome-Based Therapeutics: Review. Pharmacoepidemiology. 2026;5(1):3. doi:10.3390/pharma5010003
BibTeX
@article{Lertcanawanichakul2026,
author = {Lertcanawanichakul, Monthon and Bhoopong, Phuangthip and Madoromae, Husna and Sahabuddeen, Tuanhawanti},
title = {Clinical Use, Population-Level Impact, and Antimicrobial Resistance Considerations of Probiotics and Microbiome-Based Therapeutics: Review},
journal = {Pharmacoepidemiology},
year = {2026},
volume = {5},
number = {1},
pages = {3},
doi = {10.3390/pharma5010003}
}
EUVIMED